Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

Summary

This multi-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 40 patients aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in patients with severe illness caused be SARS-COV-2. This will be a two-arm trial comparing the SOC/best supportive care alone to the SOC/best supportive care with addition of Silmitasertib (allocation ratio 1:1).

Timeline

Start

2021-01-21

Primary completion

2022-06-30

Completion

2022-10-19

Drugs

Indications